Systematic review: The short-term and long-term efficacy of adalimumab following discontinuation of infliximab

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 10, 2009, Pages 977-986

  Ma, C ^a   Panaccione, R ^a   Heitman, S J ^a   Devlin, S M ^a   Ghosh, S ^a   Kaplan, G G ^a,b  

^a Inflammatory Bowel Disease Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; CELLULITIS; CLINICAL TRIAL; COGAN SYNDROME; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DEHYDRATION; DEMYELINATION; DRUG EFFICACY; DRUG FATALITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LIVER ABSCESS; MAJOR CLINICAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINOPATHY; REVIEW; RHINOPHARYNGITIS; SEIZURE; SKIN PRURITUS; SYSTEMATIC REVIEW; TOOTH ABSCESS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GASTROINTESTINAL AGENTS; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 71949105445     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04101.x     Document Type: Review

References (36)

1. Hanauer SB, Cohen RD, Becker RV III., Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998 20 : 1009 1028.
2. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 542 553.
3. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007 26 : 1509 1520.
4. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 333 quiz 591.
6. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56 : 1232 1239. (Pubitemid 47300424)
7. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 146 : 829 838.
8. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009 29 : 527 534.
9. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease - safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007 25 : 787 796.
10. Anwar M, O'Sullivan M, Ryan B, Breslin N, O'Connor H, O'Morain C. An open label study of adalimumab in Crohn's disease patients with a loss of response to infliximab. Gastroenterology 2006 132 : A 662.
11. Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreus MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther 2008 29 : 273 278.
12. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005 100 : 75 9.
13. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008 28 : 1122 1126.
14. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the clinical Setting. J Gastroenterol Hepatol 2009 24 : 1252 1257.
15. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008 27 : 308 315.
16. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008 135 : 1493 1499.
17. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009 58 : 940 948.
18. Karmiris K, Noman M, Vermeire S, Van Assche G, Rutgeerts P. Efficacy and safety of adalimumab in ulcerative colitis patients who failed infliximab treatment. Accessed on-line at: http://www.uegf.org/publications/abstracts2008/ abstract-detail.php?aId=OP305&navId=218. 2008.
19. Barreiro M, Echarri A, Carpio D, Pereira S, Lorenzo A, Castro J. Adalimumab maintenance therapy in fisutulizing Crohn's disease patients with intolerance or lost of response to infliximab. Accessed on-line at: http://www.uegf.org/publications/abstracts2007/abstract-detail.php?aId= 1015&navId=154. 2008.
20. Gomollon F, Hinojosa J, Nos P, Penate M, Ceballos D, Gassull MA. Long-term results of adalimumab treatment in subjects with moderately to severely active fisutlizing Crohn's diseaes who have failed response or showed intolerance to infliximab. Accessed on-line at: http://www.uegf.org/ publications/abstracts2007/abstract-detail.php?aId=1440&navId=154. 2008.
21. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clincial practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2008 29 : 286 297.
22. Burmester GR, Mease P, Dijkmans BAC, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Accessed on-line at: http://ard.bmj.com/cgi/rapidpdf/ard.2008.102103v1.
23. Hibi T, Watanabe M, Camez A, Khan M. Efficacy and Safety of Adalimumab for the Treatment of Japanese Patients with Moderately to Severely Active Crohn's Disease: results from a Randomized Controlled Trial. Am J Gastroenterol 2008 103 (S1 S414.
24. Lofberg R, Louis E, Reinisch W, Kron M, Camez A, Pollack PF. Response to Adalimumab in Bionaive and Anti-TNF expoxed patients with Crohn's Disease: results of a Phase IIIB Clinical Trial. United European Gastroenterology Federation 2008 UEGW:P0721.
25. Panaccione R, Sandborn WJ, D'Haens G, et al. Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial. Gastroenterology 2008 134 : A133.
26. Karmiris K, Noman M, Schnitzler F, et al. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. Gastroenterology 2008 134 : A658.
27. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004 10 : 333 338.
28. Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007 25 : 409 418.
29. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007 25 : 675 680. (Pubitemid 46272520)
30. Lopez Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Diaz-Rubio M. Adalimumab induction and maintenance therapy for Crohn's disease An open-label study. Spanish Journal of Gastroenterology 2008 100 : 676 681.
31. Sandborn WJ, Hanauer S, Loftus EV Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004 99 : 1984 1989.
32. Panaccione R, Loftus EV, Binion D, et al. The ACCESS Trial: adalimumab impact on remission, response, and health-related quality of life in patients with Crohn's disease. Accessed on-line at: http://www.pulsus.com/cddw2009/abs/ 123.htm.
33. Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2008 29 : 416 423.
34. Sheridan JA, Keegan D, Slattery E, Mulcahy HE, O'Donoghue DO. Adalimumab in Crohn's disease. Accessed on-line: http://www.uegf.org/publications/ abstracts2008/abstract-detail.php?aId=P0797&navId=218. 2008.
35. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
36. Sands B, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 885.